Results from the ALIGN-AR trial, investigating patients with aortic regurgitation (AR) who undergo transcatheter aortic valve replacement (TAVR) with the JenaValve Trilogy system, show that patients have an overall mortality rate of 8.1% at 1-year follow-up, compared with the prespecified goal of 25% to demonstrate noninferiority.